Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has earned a consensus recommendation of “Buy” from the eight research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $9.00.
A number of equities research analysts have weighed in on ARWR shares. ValuEngine raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Cantor Fitzgerald set a $5.00 target price on Arrowhead Pharmaceuticals and gave the company a “neutral” rating in a research report on Monday, February 12th. B. Riley lifted their target price on Arrowhead Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a research report on Monday, February 12th. BidaskClub lowered Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 14th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, February 19th.
In other news, COO Bruce D. Given sold 20,000 shares of the business’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $6.73, for a total value of $134,600.00. Following the completion of the transaction, the chief operating officer now directly owns 908,356 shares of the company’s stock, valued at approximately $6,113,235.88. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Douglas B. Given sold 25,000 shares of the business’s stock in a transaction on Tuesday, April 24th. The stock was sold at an average price of $6.63, for a total value of $165,750.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 465,000 shares of company stock valued at $3,432,350. 4.60% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. OppenheimerFunds Inc. raised its position in shares of Arrowhead Pharmaceuticals by 110.0% in the 4th quarter. OppenheimerFunds Inc. now owns 6,300,000 shares of the biotechnology company’s stock worth $23,184,000 after acquiring an additional 3,300,000 shares in the last quarter. Vanguard Capital Wealth Advisors bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth $119,000. Allianz Asset Management GmbH raised its position in shares of Arrowhead Pharmaceuticals by 2.2% in the 4th quarter. Allianz Asset Management GmbH now owns 462,105 shares of the biotechnology company’s stock worth $1,701,000 after acquiring an additional 9,985 shares in the last quarter. Macquarie Group Ltd. bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth $123,000. Finally, Quantitative Investment Management LLC bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth $203,000. 44.58% of the stock is owned by hedge funds and other institutional investors.
Shares of ARWR stock traded up $0.28 on Monday, reaching $10.05. 1,437,686 shares of the company’s stock were exchanged, compared to its average volume of 1,631,190. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.16 and a current ratio of 10.16. The firm has a market capitalization of $855.63 million, a P/E ratio of -21.38 and a beta of 2.41. Arrowhead Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $10.38.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.01. The business had revenue of $0.65 million during the quarter, compared to analyst estimates of $4.04 million. Arrowhead Pharmaceuticals had a negative return on equity of 50.05% and a negative net margin of 199.55%. sell-side analysts forecast that Arrowhead Pharmaceuticals will post -0.74 EPS for the current year.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.